Reckitt to Spend $600M on U.S. R&D Hub and Manufacturing Expansion
The Lysol and Mucinex maker is investing in domestic R&D and expanding its largest plant by half.
Reckitt, the health and hygiene company known for Lysol and Mucinex, has allotted $600 million to upgrade its U.S. operations, according to Fierce Pharma. The investment will fund an R&D hub at its new headquarters and finalize an expansion of its largest manufacturing site.
The expansion will enlarge that site by 50%, the report says. Reckitt operates seven manufacturing sites in the U.S. Since this summary is based on a single source, there are no differing accounts to compare.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.